In a recent study published in the journal Drug and Alcohol Dependence, researchers from the University of Connecticut (UConn) have found that delta-8-THC, a quasi-legal alternative to the controlled substance delta-9-THC, produces nearly identical effects in mice. This finding raises important questions about the legal distinctions between these two forms of tetrahydrocannabinol (THC), the psychoactive compound found in cannabis plants.
While delta-9-THC, the primary psychoactive component in marijuana, is classified as a Schedule 1 controlled substance by the federal government, other forms of THC, such as delta-8-THC, remain in a legal gray area. This ambiguity stems from the 2018 Farm Bill, which legalized hemp and its derivatives, including delta-8-THC, as long as they contain less than 0.3% delta-9-THC by dry weight.
The legal differences between delta-8 and delta-9-THC have led to conflicts between the hemp and cannabis industries. Cannabis producers argue that the distinction gives hemp growers an unfair advantage, as they can sell essentially the same product without the same regulations and taxes imposed on marijuana dispensaries.
The study's authors also highlight the potential risks to consumers due to the lack of regulation surrounding delta-8-THC products. Many manufacturers use solvents and chemical processes that can leave harmful residues in the final product, and there are no standards for purity or safety. Some products may contain extremely high levels of delta-8 and other THC variants, which could potentially cause harm due to the sheer dosage.
Led by UConn School of Nursing professor Steve Kinsey and graduate student Olivia Vanegas, the research team set out to replicate a study conducted in Japan in the 1980s, which showed that delta-8-THC produced the same effects in mice as delta-9-THC. The UConn researchers not only confirmed these findings but also took the investigation a step further.
By blocking the mice's THC receptors, the researchers demonstrated that delta-8-THC interacts with the same receptors as delta-9-THC. Additionally, they found that mice given delta-8-THC twice a day for five days became desensitized to its effects and exhibited withdrawal-like behavior when given a THC blocker.
In a collaboration with RTI International, the researchers conducted an experiment in which mice were trained to go to a specific location for a reward when dosed with delta-9-THC. When the mice were subsequently dosed with delta-8-THC, they went to the same reward location, indicating that the effects of the two compounds were similar.
"So they're telling us the same thing people buying the stuff in gas stations tell us: Δ8 feels like THC," Kinsey explains.
The UConn study's findings have significant implications for the regulation of THC and its various forms. If the justification for regulating delta-9-THC as an illegal drug is based on its psychoactive effects, then the evidence that delta-8-THC produces similar effects raises questions about the rational basis for its quasi-legal status.
John Harloe, an attorney on Colorado's THC taskforce, plans to present the UConn study to inform the ongoing discussion about appropriate regulation of different THC variants. The taskforce aims to create regulations that address public safety concerns without crippling the hemp industry.
The study's authors emphasize the need for further research on THC and its intoxicating effects, which has been limited due to federal restrictions. As the legal landscape surrounding cannabis and its derivatives continues to evolve, scientific evidence will play an increasingly important role in shaping rational and effective policies.
